Effective Wednesday, August 18, 2021, to align with Clinical and Laboratory Standards Institute (CLSI) guidelines, the Salicylate lower limit of reporting will increase from 0.3 mg/dL to 2.0 mg/dL.
Note: The therapeutic range for Salicylate is 2.0 – 10.0 mg/dL and this test is best utilized for assessment of Salicylate toxicity.
Salicylate Level – Test Codes: Epic #LAB34, Interface #10245, CPT #80329
Mayo Clinic recently completed a four-year review of Myasthenia Gravis serum evaluations and will be implementing changes to our testing algorithm.
Effective March 17, 2021, COVID-19 Serology Testing will be updated from COVID-19 IgG Antibody to COVID-19 Total Antibody
Spectrum Health Immunochemistry Laboratory is pleased to announce 5 new allergen tests and the addition of Tryptase. The following allergens are now available:
Effective December 9, 2020, the following insect allergen components will be available:
◊ Allergen Honey Bee Component Panel – EPIC #LAB1230747, Interface #1230747, CPT 86008
◊ Allergen Common Wasp (Yellow Jacket) Component Panel – EPIC #LAB1230752, Interface #1230752, CPT 86008
◊ Allergen Paper Wasp Component rPol d 5 – EPIC #LAB1230754, Interface #1230754, CPT 86008
◊ Cross-reactive Carbohydrate Determinant (CCD) – EPIC #LAB1230755, Interface #1230755, CPT 86008
As of February 11, 2021, this has been resolved. Testing has resumed at Spectrum Health Regional Laboratory Immunochemistry Department.
Starting November 1, 2020, the Lyme Total Antibody test will temporarily not be performed in-house and will be sent out to the Mayo Clinic Laboratories using the Lyme Disease Serology, Serum. This is due to the backorder of reagents from the vendor until approximately January 2021.
Lyme Disease Serology, Serum is available to order in Epic. Lyme Total Antibody will still be available to order, however, when the specimen arrives to the laboratory the order will be switched to the Lyme Disease Serology, Serum.
Similarly, to the current in-house test, the Mayo assay is also a Lyme total antibody assay, detecting both IgG and IgM antibodies, with the same specimen type as the in-house test. However, test turn-around-times may be increased.
Lastly, this change will have no effect on the reflexing of positive samples to the confirmatory Lyme Disease Antibody, Immunoblot, Serum.
Effective September 28th, 2020, a new generation of the serum kappa/lambda free light chain assay has been implemented.
With the implementation of the new generation of the assay there is an approximately 20% negative bias for kappa free light chains in serum containing >20 mg/dL kappa free light chain. This may affect the trending for patient who are serially monitored by this assay.
As of August 26, 2020, the following tests will be obsoleted or made as lab orderables only. This was implemented to streamline protein electrophoresis orders and ensure that patients receive the recommended testing for the assessment of plasma cell proliferative diseases.
In addition to streamlining protein electrophoresis orders, order questions have been implemented to the available tests to access the reason for ordering to ensure that the proper reflex testing is applied.
For more information, see the lab test directory under the available tests for a protein electrophoresis orders tip sheet entitled “Orders- Protein Orderable Changes”
Effective April 22nd, 2020, the following ANA (Antinuclear Antibodies) Tests’ name will be updated. The change in naming convention comes in hopes of enhancing proper test utilization. This update includes only the name change with no changes in laboratory testing workflow.